{"id":12102,"date":"2026-11-12T18:55:00","date_gmt":"2026-11-12T13:25:00","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-11-12\/"},"modified":"2026-11-12T18:55:03","modified_gmt":"2026-11-12T13:25:03","slug":"alkem-share-price-today-2026-11-12","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-11-12\/","title":{"rendered":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 2.68% | 12 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ALKEM<\/strong> \u00b7 12 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b95,302.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-2.68%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b95,422.00 \/ \u20b95,173.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b95,448.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>10.00 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>12 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Alkem Laboratories Ltd. (ALKEM) declined by 2.68% on Wednesday, closing at \u20b95,302.0 after moving within a wide intraday range between a low of \u20b95,173.0 and a high of \u20b95,422.0.<\/li>\n<li>Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named &#x27;Alkem Pharma Company&#x27; as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.<\/li>\n<li>Trading volume was 9.44 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Alkem Laboratories share price falling on 12 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Alkem Laboratories Ltd. (ALKEM) declined by 2.68% on Wednesday, closing at \u20b95,302.0 after moving within a wide intraday range between a low of \u20b95,173.0 and a high of \u20b95,422.0.<\/p>\n<p class=\"wt-copy\">The broader market showed modest positive momentum, with the benchmark Nifty index rising by 0.18%, whereas the Nifty Pharma sector index edged down by 0.35%. Alkem&#x27;s decline outpaced the sectoral softness, contrasting with its recent multi-day performance that included a 5-day return of 1.64% and a 20-day return of 0.99%.<\/p>\n<p class=\"wt-copy\">Company filings provided fresh context following the announcement of its standalone and consolidated financial results for the quarter ended September 30, 2026. Alkem reported a 13.8% year-on-year growth in total revenue from operations at \u20b945,520 million, supported by domestic sales of \u20b930,275 million and international sales of \u20b914,540 million. However, net profit after non-controlling interest declined 11.7% year-on-year to \u20b96,753 million, largely impacted by a higher effective tax rate and increased operating costs from the Enzene CDMO business and the integration of Occlutech.<\/p>\n<p class=\"wt-copy\">10.00 lakh shares traded by 12 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 1.06 lakh shares (9.44 times). The five-day average daily volume was 1.05 lakh shares. Separately, the NSE report for 12 November 2026 showed 2.67 lakh shares delivered, representing 26.66% of that day\u2019s traded volume. The same report recorded 88,996 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Earnings release reaction and profit-taking after recent gains<\/strong><\/p>\n<p class=\"wt-copy\">The stock declined 2.68% amid heavy volume following the release of Q2 FY27 financial results, which showed strong top-line revenue growth accompanied by an 11.7% decline in net profit due to higher tax provisions and operating expenses.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Incorporation of Saudi Arabian Joint Venture Subsidiary<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named &#x27;Alkem Pharma Company&#x27; as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.<\/p>\n<p class=\"wt-copy\">Expands Alkem&#x27;s operational footprint and market reach into the Middle Eastern pharmaceutical sector.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08112026184401_Draft_Reg_30_Incorporation_of_JV_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Investment \/ acquisition update<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Intimation of incorporation of subsidiary in the form of Joint Venture.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08112026184401_Draft_Reg_30_Incorporation_of_JV_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 16, 2026, titled &quot;Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">49.70%<\/div>\n<div class=\"wt-note\">51.20% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.42%<\/div>\n<div class=\"wt-note\">10.16% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">33.05%<\/div>\n<div class=\"wt-note\">31.56% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 29 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund &#8211; Hdfc Mid-Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">57.07 lakh shares \u00b7 4.77%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Multi-Asset Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">42.68 lakh shares \u00b7 3.57%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Large &amp; Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">23.83 lakh shares \u00b7 1.99%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">17 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b95,770.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a Neutral rating following earlier earnings performance while adjusting the target price to reflect valuation parameters and ongoing execution dynamics.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JAYANTI SINHA<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 12.38 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 9.04 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SAMPRADA&amp;NANHAMATI SINGH FAMILY TRUST<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 5.50 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.10 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Post-earnings analyst commentary and management guidance on operating margins and tax rates.<\/li>\n<li>Remediation progress and follow-up updates regarding the Daman formulations facility regulatory status.<\/li>\n<li>Execution and scaling of the newly incorporated Saudi Arabian joint venture subsidiary.<\/li>\n<li>Performance trends in international markets and integration milestones for Occlutech.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-23\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-22\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.03% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/alkem\/\">More Alkem Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Alkem Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Alkem completed the incorporation of a subsidiary in the Kingdom of Saudi Arabia named &#x27;Alkem Pharma Company&#x27; as a limited liability joint venture. The company subscribed to 38,250 shares amounting to 3,825,000 SAR, securing a 51% controlling stake to manufacture, import, and distribute pharmaceutical and nutraceutical products in the region.<\/p>\n<h3>How strong was Alkem Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">10.00 lakh shares traded, 9.44 times the 20-day average daily volume. The price and volume data are dated 12 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-11-12\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-11-12\/\"}, \"headline\": \"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 2.68% | 12 November 2026\", \"description\": \"Alkem Laboratories share price fell 2.68% to \u20b95,302.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-12T18:54:49.197734+05:30\", \"dateModified\": \"2026-11-12T18:54:49.197734+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Alkem Laboratories\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"ALKEM\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/alkem-company-news-2026-11-12.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Appointment\",\"summary\":\"Appointment of Mr Gopal Kothari as Chief Financial Officer of the Company w.e.f. December 02, 2026.\",\"source\":\"NSE\",\"published\":\"12-Nov-2026 13:58:25\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12112026135747_Reg30AppointmentofCFO.pdf\",\"disclosure_text\":\"12th November, 2026 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM Dear Sir\/Madam, Sub: Disclosure under Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (\u201cSEBI Listing Regulations\u201d): Appointment of Chief Financial Officer We wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee and approval of the Audit Committee, the Board of Directors of the Company at its meeting held today i.e. 12th November, 2026 has appointed Mr. Gopal Kothari as the Chief Financial Officer (CFO) and Key Managerial Pers onnel of the Company with effect from 02nd December, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 01.40 p.m. Further, the details as required in terms of Regulation 30 read with Schedule III, Part A of the SEBI LODR Regulations and SEBI Master Circular bearing HO\/49\/14\/14(7)2025- CFDPOD2\/I\/3762\/2026 dated January 30, 2026 are provided in Annexure I to this letter. The above information is also available on the website of the Company www.alkemlabs.com. Kindly take the same on your records. Sincerely, For Alkem Laboratories Limited Manish Narang President - Legal, Company Secretary & Compliance Officer Encl: a\/a Annexure I Sr. No. Particulars Details 1. Name Mr. Gopal Kothari 2. Reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise Appointment 3. Date of appointment\/ re-appointment\/ cessation (as applicable) and term of appointment\/ reappointment Date of appointment: 02nd December, 2026 Term of appointment : Duration of the contract shall be so long as he is in employment of the Company. 4. Brief Profile Mr. Gopal Kothari has over 24 years of experience in Financial Planning & Analysis, Business Partnering, Cash Flow Management, Business Finance, Cost Management & Productivity, Enabling Growth, Taxation, Management Reporting, Finance Control, dealing with Board of Directors, Business Integration and New Products Development. Mr. Kothari is a qualified Chartered Accountant (CA) and Company Secretary (CS) , and holds B. Com. (Honours) degree. 5. Disclosure of relationships between directors NA\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"12-Nov-2026 13:54:26\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12112026135201_AlkemReg3312112026.pdf\",\"disclosure_text\":\"\u00a2> _ ALKEM _ Inspiring Healthier Lives 12th November, 2026 To, ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE,;Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. \u2022 Phone: +91-22-398? ~9999 \u2022 Fax: 022-2495 2955 \u2022 Email: contact@alkem .com \u2022 Website : www .alkemlabs.com \u2022 GIN : L00305MH1973PLC174201 The Corporate Relationship Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrq1Code:539523 Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Svmbol: ALKEM Sub: Outcome of the Board Meeting held on 12th November, 2026 Dear Sir(s)\/ Madam, This is in reference to our earlier intimation dated 04th November, 2026, pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\\\"SEBI LODR Regulations\\\"), regarding holding of Board Meeting on 12th November, 2026 to inter alia approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. The Board of Directors at its meeting held today, i.e. 12th November, 2026 has approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September , 2026. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the SEBI LODR Regulations , is enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 01.40 p.m. The above information is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Sincerely, For Alkem Laboratories Limited LJ . \\\"-Jc.\\u002d\\u002d\\u002d\\u002d~ Manish Narang President - Legal, Company Secretary & Compliance Officer Encl.: a\/a Deloitte Haskins & Sells LLP Chartered Accountants One International Center, Tower 3, 31st Floor, Senapati Bapat Marg Elphinstone Road (West) Mumbai - 400 013 Maharashtra, India Tel: +91 22 6185 6000 Fax: +91226185 4101 INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF ALKEM LABORATORIES LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Alkem Laboratories Limited (\\\"the Parent\\\") and its subsidiaries (the Parent and its subsidiaries together referred to as \\\"the Group\\\") and its share of the net loss after tax and total comprehensive income of its associate for the quarter and six months ended September 30, 2026 (\\\"the Statement\\\") which includes the branch of the Group located at Nepal, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (\\\"the Listing Regulations\\\"). 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 \\\"Interim Financial Reporting\\\" (''Ind AS 34\\\"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 \\\"Review of Interim Financial Information Performed by the Independent Auditor of the Entity\\\", issued by the Institute of Chartered Accountants of India (!CAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure 1 to this report. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. \\\\ Regd. Office: One International Center, Tower 3, 31st floor, Senapati Ba pat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability\\\"having LLP identification No: MB-8737 Deloitte Haskins & Sells LLP 6. We did not review the interim financial information \/ financial resu lts of five subsidiaries included in the consolidated unaud ited financial results, whose interim financial information \/ financial results reflect total assets of Rs.15,803.8 million as\u00b7 at September 30,2026 and, total revenues of Rs.6,013.9 million and Rs.8,959.0 million for the quarter and six months ended September 30, 2026 respectively, total net profit after tax of Rs.401.6 million and Rs.449.4 mill ion for the quarter and six months ended September 30,2026 respectively and total comprehensive income of Rs. 348.3 mill ion and Rs.414.6 million for the quarter and six months ended September 30,2026 respectively and net cash inflow of Rs.30.8 million for the six months ended September 30,2026, as considered in the Statement . These interim financial information \/ financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. 7. The consolidated unaudited financial results includes the interim financial information of twenty eight subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs.11,605. 5 million as at September 30,2026 and, total revenue of Rs.1,661. 7 million and Rs.3,923. 7 million for the quarter and six months ended September 30, 2026 respectively, total net loss after tax of Rs.284.2 million and Rs.384.9 million for the quarter and six months ended September 30,2026 respectively and total comprehensive income of (Rs. 274.7 million) and (Rs.357.5 million) for the quarter and six months ended September 30,2026 respectively and net cash inflow of Rs.650.9 million for the six months ended September 30,2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs.6.1 million and Rs.11. 2 million for the quarter and six months ended September 30,2026 respectively and total comprehensive income of (Rs.6.1 million) and (Rs.11.2 m illion) for the quarter and six months ended September 30,2026 respectively, as considered in the Statement, in respect of one associate, based on its interim financial information which has not been reviewed by its auditor. According to the information and explanations given to us by the Management, these interim financial informat ion are not material to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information \/ results cert ified by the Management . l Place : Mumbai Date: November 12, 2026 For Deloitte Haskins & Sells LLP Chartered Accountants (F irm's Registration No. 117366W\/W-100018) Rupen K. Bhatt (Partner) (Membership No. 046930) (UDIN: 26046930 DhlPN 1y q 482 ) Deloitte Haskins & Sells LLP ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT (Referred to in paragraph 4 under Independent Auditor's Review Report of even date) S.N. Name of the component Relationship 1 Alkem Laboratories Limited Parent 2 S&B Holdinqs S.a.r.l Wholly Owned Subsidiary 3 The Pharma Network LLC, USA (TPN) Wholly Owned Subsidiary of S&B Holdings S.a.r.l. 4 Ascend Laboratories LLC, USA Wholly Owned Subsidiary of TPN 5 S & B Pharma LLC Wholly Owned Subsidiary of TPN 6 Pharmacor Pty Limited, Australia Wholly Owned Subsidiary 7 Pharmacor SPA, Chile Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia 8 Enzene Biosciences ltd, India Subsidiary 9 Ascend Laboratories (PTY) Ltd, South Africa Wholly Owned Subsidiary 10 Cachet Pharmaceuticals Private Limited, India Subsidiary 11 lndchemie Health Specialties Private Limited, Subsidiary India 12 Alkem Laboratories Corporation, Philippines Wholly Owned Subsidiary 13 Ascend GmbH, Germany Wholly Owned Subsidiary 14 Ascend Laboratories SON BHD., Malaysia Wholly Owned Subsidiary 15 Ascend Laboratories SpA Chile (Ascend Chile) Wholly Owned Subsidiary 16 Pharma Network SpA, Chile Wholly Owned Subsidiary of Ascend Chile 17 Ascend Laboratories S.A. DE C.V., Mexico Wholly Owned Subsidiary of Ascend Chile 18 Alkem Laboratories Korea Inc, Korea Wholly Owned Subsidiary 19 Pharmacor Ltd, Kenya Wholly Owned Subsidiary 20 The Pharma Network LLP, Kazakhstan Wholly Owned Subsidiary 21 Ascend Laboratories (UK) Ltd, UK Wholly Owned Subsidiary 22 Ascend Laboratories Ltd, Canada Wholly Owned Subsidiary 23 Alkem Foundation, India Wholly Owned Subsidiary 24 Connect 2 Clinic Private Limited, India Wholly Owned Subsidiary 25 Ascend Laboratories SAS, Colombia Wholly Owned Subsidiary 26 Pharmacor Limited, New Zealand Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia 27 Enzene Inc., USA Wholly Owned Subsidiary of Enzene Biosciences Ltd, India 28 Alkem Medtech Private Limited, India Wholly Owned Subsidiary 29 Alkem Medtech Ortho Private Limited (w.e.f 16 Wholly Owned Subsidiary of Alkem April 2025) Medtech Private Limited 30 Alixer Nexgen Therapeutics Limited Wholly Owned Subsidiary 31 Alkem Wellness Limited Wholly Owned Subsidiary 32 Adroit Biomed Limited, India (w.e.f 23 April Wholly Owned Subsidiary 2025) 33 Alkem Pharmaceuticals Scientific Office FZ LLC, Wholly Owned Subsidiary Dubai (incorporated on 4 February 2026) 34 Alkem Pharma Trading FZCO, Dubai Wholly Owned Subsidiary (incorporated on 27 March 2026) 35 Haystack Analytics Private Limited Associate 36 Occlutech Holding AG (Switzerland)(w.e.f 16 Subsidiary of Alkem MedTech Private July 2026) Limited 37 Occlutech AG (Switzerland) Wholly Owned Subsidiary of Occlutech Holdinq AG (Switzerland) Deloitte Haskins & Sells LLP 38 Occlutech Gmbh (Germany) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 39 Occlutech International AB (Sweden) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 40 Occlutech Tibbi Urunler Sanayi ve Ticaret Ltd Wholly Owned Subsidiary of Occlutech Sirketi (Turkey) AG (Switzerland) 41 Occlutech France Sari (France) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 42 Occlutech Italia s.r.l (Italy) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 43 Occl utech Uk Ltd (UK) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 44 Occlutech US LLC (US) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 45 OCCLUTECH POLAND SPOlKA Z Wholly Owned Subsidiary of Occlutech OGRANICZONA. ODPOWIEDZIALNOSCIA. AG (Switzerland) (Poland) 46 Occlutech Canada Inc. (Canada) Wholly Owned Subsidiary of Occlutech AG (Switzerland) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ALKEM LABORATORIES LIMITED CIN No.: L00305MH 1973PLC 17 4201 Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India. Tel No:91 22 3982 9999 Fax No: +91222492 7190 Website : www.alkemlabs.com, Email Id : investors@alkem.com Statement of Consolidated Financial Results for the Quarter and Six months ended 30 September 2026 (f in Million except per share data) Quarter ended Six months ended Year ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income (a) Revenue from Operations 45,519.9 37,401.5 40,009.9 82,921.4 73,721.3 147,122.7 (b) other Income 1,342.1 1,527.5 1,036.9 2,869.6 2,401.8 5,833.5 Total Income 46,862.0 38,929.0 41,046.8 85,791.0 76,123.1 152,956.2 Expenses (a) Cost of materials consumed 10,830.3 9,100.2 9,055.7 19,930.5 17,326.8 35,653.9 (b) Purchases of stock-in-trade 4,688.3 3,659.9 4,715.7 8,348.2 8,687.7 16,945.0 (c) Changes in inventories of finished goods, work-in- (571.1) (747.4) 238.9 (1,318.5) (292.6) (1,671.2) progress and stock-in-trade (d) Employee benefits expense 8,965.2 8,089.0 7,102.5 17,054.2 14,035.0 28,371.1 (e) Finance costs 576.7 466.2 350.2 1,042.9 648.0 1,607.8 (f) Depreciation and amortisation expense 1,370.8 1,001.9 936.1 2,372.7 1,812.9 3,820.6 (g) Other expenses 11,355.3 9,639.3 9,689.4 20,994.6 17,366.2 37,771.8 Total Expenses 37,215.5 31,209.1 32,088.5 68,424.6 59,584.0 122,499.0 Profit before exceptional items and tax (1) - (2) 9,646.5 7,719.9 8,958.3 17,366.4 16,539.1 30,457.2 Exceptional items (refer note 3) 350.0 - - 350.0 129.3 (1,748.3) Profit before tax (3) + (4) 9,996.5 7,719.9 8,958.3 17,716.4 16,668.4 28,708.9 Tax expense I (credit) (Refer note 4) (a) Current tax 4,053.4 2,320.6 1,799.5 6,374.0 3,210.6 6,196.6 (b) Deferred tax (734.3) 184.4 (637.2) (549.9) (1,021.4) (1,019.0) Total Tax Expense (a + b) 3,319.1 2,505.0 1,162.3 5,824.1 2,189.2 5,177.6 Share in loss after tax of associate (6.1) (5.1) (4.9) (11.2) (9.0) (19.7) Profit for the period (5) - (6) + (7) 6,671.3 5,209.8 7,791.1 11,881.1 14,470.2 23,511.6 Other Comprehensive lncome\/(Loss) (net of tax) (a) (i) Items that will not be reclassified to profit or loss (29.0) (25.4) (44.9) (54.4) (92.5) 120.9 (ii) Income tax relating to items that will not be 5.4 8.4 26.6 13.8 29.5 (38.1} reclassified to profit or loss (b) (i) Items that will be reclassified to profit or loss (92.3) 45.8 447.0 (46.5) 512.5 1,755.1 (ii) Income tax relating to items that will be reclassified to profit or loss - - - Total Other Comprehensive lncome\/(Loss) (net of tax) (115.9) 28.8 428.7 (87.1) 449.5 1,837.9 Total Comprehensive Income for the period 6,555.4 5,238.6 8,219.8 11,794.0 14,919.7 25,349.5 (8) + (9) Profit attributable to a) Owners of the Company 6,753.4 5,199.6 7,650.6 11,953.0 14,293.2 23,018.0 b) Non-Controlling Interest (82.1) 10.2 140.5 (71.9) 177.0 493.6 Other Comprehensive lncome\/(Loss) attributable to - a) Owners of the Company (77.0) 29.0 432.4 (48.0) 455.5 1,823.8 b) Non-Controlling Interest (38.9) (0.2) (3.7) (39.1) (6.0) 14.1 Total Comprehensive Income attributable to - a) Owners of the Company 6,676.4 5,228.5 8,083.0 11,905.0 14,748.7 24,841.8 b) Non-Controlling Interest (121.0) 10.1 136.8 (111.0) 171.0 507.7 Paid-up Equity Share Capital (Face Value f 2 each fully paid up) 239.1 239.1 239.1 239.1 239.1 239.1 Other Equity 137,961.9 Earnings Per Share (not annualised for the periods) (face value off 2\/- each) (a) Basic (f) 56.48 43.49 63.99 99.97 119.55 192.51 (b) Diluted (f) 56.48 43.49 63.99 99.97 119.55 192.51 Statement of Consolidated Assets and Liabilities as at 30 September 2026 (~ in Million) As at As at Particulars 30 September 31 March 2026 2026 (Unaudited) (Audited) I. ASSETS 1 Non-current assets (a) Property, plant and equipment 27,074.5 26,949.7 (b) Right of use assets 4,466.7 3,956.6 (c) Capital work-in-progress 1,607.9 1,379.1 (d) Goodwill 12,210.2 5,236.4 (e) Other intangible assets 13,607.6 2,567.6 (f) Intangible assets under development 1,421.9 1,438.8 (g) Financial Assets (i) Investment in associate 336.9 348.1 (ii) Other investments 11,834.4 10,966.9 (iii) Other financial assets 7,249.8 12,157.4 (h) Deferred tax assets (net) 17,471.8 18,193.5 (i) Current tax assets (net) 836.9 799.6 U) Other non-current assets 2,656.4 2,630.8 Total Non-current assets 100,775.0 86,624.5 2 Current assets (a) Inventories 35,252.7 33,332.2 (b) Financial Assets (i) Investments 8,559.7 7,373.1 (ii) Trade receivables 33,700.5 29,791.1 (iii) Cash and cash equivalents 4,084.3 2,479.1 (iv) Bank balances other than (iii) above 2,091.0 14,849.9 (v) Loans 90.9 66.3 (vi) Other financial assets 35,789.2 25,225.2 (c) Other current assets 10,253.1 8,988.3 Total Current assets 129,821.4 122,105.2 TOT AL ASSETS 230,596.4 208,729.7 II. EQUITY AND LIABILITIES 1 Equity (a) Equity share capital 239.1 239.1 (b) Other Equity 148,413.0 137,961.9 Equity attributable to owners of the Company 148,652.1 138,201.0 (c) Non-controlling interest 8,237.9 5,288.3 Total Equity 156,890.0 143,489.3 2 Non-current liabilities (a) Financial Liabilities (i) Borrowings 10,334.6 4,924.5 (ii) Lease liabilities 3,889.7 3,767.8 (iii) Other financial liabilities 5,779.0 4,077.0 (b) Provisions 4,416.4 4,312.1 (c) Deferred tax liabilities (net) 2,033.9 151.2 (d) Other non-current liabilities 161.9 180.8 Total Non-current liabilities 26,615.5 17,413.4 3 Current liabilities (a) Financial Liabilities (i) Borrowings 8,2\"}],\"recent_news\":[{\"summary\":\"Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"12-Nov-2026 13:54:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12112026135201_AlkemReg3312112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Intimation of incorporation of subsidiary in the form of Joint Venture.\",\"category\":\"General Updates\",\"date\":\"08-Nov-2026 18:44:19\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08112026184401_Draft_Reg_30_Incorporation_of_JV_signed.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"An NSE promoter pledge\/encumbrance filing was identified, but the available filing text could not be reduced reliably to a concise current pledge figure.\",\"events\":[{\"summary\":\"le Marg, Worli, Mumbai - 400030 National Stock Exchange of India Limited \\\"Exchange Plaza\\\", 5th Floor, Plot No. C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 051 Symbol: ALKEM Sub: Declaration pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir\/ Madam, Pmsuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeove rs) Regulations, 2011, I, Basudeo N. Singh, promoter of Alkem Laboratories Limited, on behalf of all promoters\/ members of promoters group along with person acting in concert, hereby declare that we have not mad e any encumbrance, directly or indirectly, during the finan cial year 2025-26. The above is for your information and record. Thanking You Yours Sincerely, For and on behalf of Promot er(s) of Alkem Laboratories Limited ~(\\\\),?<:~\/ Basudeo N. Singh Promoter CC: Audit Committee Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013 Maharashtra, India\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"07-Apr-2026 14:30:02\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_06042026134202_Reg_3.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":49.7,\"public_pct\":50.3,\"fii_pct\":10.42,\"dii_pct\":22.63,\"mf_pct\":16.71,\"institutional_pct\":33.05,\"noninst_pct\":17.25,\"mf_scheme_count\":29,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund - Hdfc Mid-Cap Fund\",\"shares\":5706750,\"pct\":4.77},{\"name\":\"Icici Prudential Multi-Asset Fund\",\"shares\":4268472,\"pct\":3.57},{\"name\":\"Sbi Large &amp; Midcap Fund\",\"shares\":2383162,\"pct\":1.99},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":2234434,\"pct\":1.87},{\"name\":\"Dsp Midcap Fund\",\"shares\":2132118,\"pct\":1.78}],\"period\":\"30-JUN-2026\",\"submission_date\":\"09-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":51.2,\"previous_fii_pct\":10.16,\"previous_dii_pct\":21.4,\"previous_mf_pct\":15.57,\"previous_institutional_pct\":31.56,\"previous_mf_scheme_count\":30,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"5770\",\"view_summary\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why NDTV Profit\",\"headline\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why\",\"published\":\"2026-08-17T07:00:00+00:00\",\"source\":\"NDTV Profit\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"JAYANTI SINHA\",\"side\":\"Sell\",\"quantity\":\"12,38,220\",\"price\":\"5,200\",\"value\":\"\u20b9643.87 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"ICICI PRUDENTIAL MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"9,03,527\",\"price\":\"5,200\",\"value\":\"\u20b9469.83 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SAMPRADA&NANHAMATI SINGH FAMILY TRUST\",\"side\":\"Sell\",\"quantity\":\"5,50,000\",\"price\":\"5,200\",\"value\":\"\u20b9286.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"HDFC MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"5,09,615\",\"price\":\"5,200\",\"value\":\"\u20b9265.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"DSP MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"86,538\",\"price\":\"5,200\",\"value\":\"\u20b945.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SOCIETE GENERALE\",\"side\":\"Buy\",\"quantity\":\"48,090\",\"price\":\"5,200\",\"value\":\"\u20b925.01 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Nippon India Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Morgan Stanley Asia Singapore Pte\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alkem Laboratories share price fell 2.68% to \u20b95,302.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":12101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 2.68% | 12 November 2026","_witty_meta_description":"Alkem Laboratories share price fell 2.68% to \u20b95,302.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Alkem Laboratories share price today","_witty_reason_label":"Earnings release reaction and profit-taking after recent gains","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[143],"class_list":["post-12102","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-alkem"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=12102"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12102\/revisions"}],"predecessor-version":[{"id":12103,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12102\/revisions\/12103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/12101"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=12102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=12102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=12102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}